Get the Stockscreener App
7.095
1.39%
0.095
Abeona Therapeutics Inc stock is traded at $7.095, with a volume of 425.09K.
It is up +1.39% in the last 24 hours and up +5.14% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$7.00
Open:
$6.96
24h Volume:
425.09K
Relative Volume:
0.46
Market Cap:
$363.56M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-2.75
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
-1.84%
1M Performance:
+5.14%
6M Performance:
+22.79%
1Y Performance:
+35.44%
1-Day Range:
$6.94
$7.145
1-Week Range:
$6.70
$7.5401
52-Week Range:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
7.09 | 353.49M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.34 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
601.02 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.60 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.26 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.09 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Chartists See Breakout Potential in Abeona Therapeutics Inc.July 2025 WrapUp & High Accuracy Swing Entry Alerts - newsyoung.net
Institutional scanner results for Abeona Therapeutics Inc.2025 Winners & Losers & AI Driven Stock Reports - Newser
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q2 2025 Earnings Call Transcript - Insider Monkey
What to expect from Abeona Therapeutics Inc. in the next 30 daysJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
Using economic indicators to assess Abeona Therapeutics Inc. potential2025 Technical Overview & Stock Portfolio Risk Management - Newser
Backtesting results for Abeona Therapeutics Inc. trading strategiesQuarterly Market Review & Daily Profit Maximizing Trade Tips - Newser
Leading vs lagging indicators on Abeona Therapeutics Inc. performanceQuarterly Market Summary & Verified Chart Pattern Signals - Newser
Real time breakdown of Abeona Therapeutics Inc. stock performancePortfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - Newser
What MACD and RSI say about Abeona Therapeutics Inc.July 2025 PreEarnings & Reliable Breakout Stock Forecasts - Newser
What’s the recovery path for long term holders of Abeona Therapeutics Inc.2025 Breakouts & Breakdowns & Advanced Technical Signal Analysis - Newser
Abeona Therapeutics Inc.’s volatility index tracking explained2025 Geopolitical Influence & AI Driven Price Predictions - Newser
What the charts say about Abeona Therapeutics Inc. todayShare Buyback & AI Powered Market Entry Ideas - Newser
How to forecast Abeona Therapeutics Inc. trends using time series2025 Growth vs Value & Scalable Portfolio Growth Methods - Newser
What technical models suggest about Abeona Therapeutics Inc.’s comebackStop Loss & Weekly High Return Opportunities - Newser
Abeona Therapeutics (ABEO) Gets a Buy from H.C. Wainwright - The Globe and Mail
ABEO: First Patient Treatment with Zevaskyn Expected in 3Q25 - Research Tree
Abeona Therapeutics Inc. stock trend outlook and recovery pathTrade Signal Summary & Capital Efficient Trading Techniques - Newser
Can Abeona Therapeutics Inc. maintain sales growthPortfolio Gains Summary & Accurate Intraday Trading Signals - thegnnews.com
Will Abeona Therapeutics Inc. continue its uptrendJuly 2025 Fed Impact & Daily Stock Trend Reports - Newser
Abeona Therapeutics Inc. stock chart pattern explainedEarnings Performance Report & Weekly Sector Rotation Insights - Newser
Abeona Therapeutics Executives Offload Stock Amid Financial Turnaround - AInvest
Top Executives Offload Abeona Therapeutics Stock in Major Transactions - TipRanks
Abeona Therapeutics director Crombez sells $33k in shares - Investing.com
Abeona Therapeutics director Crombez sells $33k in shares By Investing.com - Investing.com South Africa
Abeona Therapeutics CFO sells $110k in stock - Investing.com India
Abeona Therapeutics CFO sells $110k in stock By Investing.com - Investing.com UK
Abeona Therapeutics: AAV204 Capsid Licensing as a New Growth Engine - AInvest
Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn (ABEO) - Seeking Alpha
Abeona Therapeutics price target raised to $20 from $19 at Oppenheimer - TipRanks
How to read the order book for Abeona Therapeutics Inc.Market Risk Analysis & Reliable Price Action Trade Plans - Newser
Oppenheimer Adjusts Abeona Therapeutics Price Target to $20 From $19, Maintains Outperform Rating - MarketScreener
Earnings call transcript: Abeona Therapeutics Q2 2025 reports unexpected profit - Investing.com
Abeona Therapeutics: Q2 Earnings Snapshot - Stamford Advocate
Screener Results Flag Abeona Therapeutics Inc. as OversoldJuly 2025 PreEarnings & AI Forecasted Stock Moves - beatles.ru
Abeona Posts Q2 Profit on Asset Sale - AOL.com
Abeona Therapeutics Reports Strong Financial Turnaround - TipRanks
Abeona Therapeutics Inc. stock outlook for YEARPortfolio Growth Summary & Stepwise Trade Execution Plans - Newser
Abeona Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingCEO Change & AI Enhanced Trading Alerts - beatles.ru
Abeona Therapeutics' Q2 2025 Earnings: A Catalyst-Driven Path to Commercialization and Profitability - AInvest
Transcript : Abeona Therapeutics Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Abeona Therapeutics reports Q2 EPS ($1.71) vs (26c) last year - TipRanks
Abeona Therapeutics Shakes Off Losses With A Surprise Profit - Finimize
Abeona Therapeutics shares rise 6.71% premarket after reporting Q2 net income of $108.8 million, beating Wall Street expectations. - AInvest
Abeona Therapeutics Receives FDA Approval for ZEVASKYN™: First Autologous Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa with Launch Expected in 2025 - Quiver Quantitative
Abeona Therapeutics Q2 net income beats estimates on PRV sale, sees profitability in H1 2026 - MarketScreener
ABEONA THERAPEUTICS INC. SEC 10-Q Report - TradingView
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abeona Therapeutics Inc Stock (ABEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vazzano Joseph Walter | Chief Financial Officer |
Aug 15 '25 |
Sale |
7.36 |
15,000 |
110,358 |
462,666 |
0.95%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):